Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 171-172

  Pitini, Vincenzo ^a   Arrigo, Carmela ^a   Di Mirto, Cristian ^a   Mondello, Patrizia ^a   Altavilla, Giuseppe ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Chronic myelogenous leukemia; Dasatinib; DDR2; Driver mutations; Squamous cell carcinoma; Targeted therapies

Indexed keywords

DASATINIB; DISCOID RECEPTOR 2; PHOSPHOTRANSFERASE; RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER STAGING; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOGENETICS; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; LEUKOCYTOSIS; LUNG LOBECTOMY; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE DISSECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SMOKING; SOMATIC MUTATION; THORAX PAIN; THORAX RADIOGRAPHY; TRANSTHORACIC BIOPSY;

CHRONIC MYELOGENOUS LEUKEMIA; DASATINIB; DDR2; DRIVER MUTATIONS; SQUAMOUS-CELL CARCINOMA; TARGETED THERAPIES;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUNG NEOPLASMS; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASMS, MULTIPLE PRIMARY; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, MITOGEN; THIAZOLES; TREATMENT OUTCOME;

EID: 84884412102     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.07.004     Document Type: Article

References (7)

1. Labrador J.P., Azcoitia V., Tuckermann J., Lin C., Olaso E., Mañes S., et al. The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. EMBO Rep 2001, 2(May (5)):446-452.
2. Hammerman P.S., Sos M.L., Ramos A.H., Xu C., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011, 1(June (1)):78-89. 10.1158/2159-8274.CD-11-0005.
3. Day E., Waters B., Spiegel K., et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008, 599:44-53.
4. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489(September (7417)):519-525. doi:10.1038/nature11404. Epub 2012 Sep 9. Erratum in: Nature. 2012 Nov 8;491(7423):288. Rogers, Kristen [corrected to Rodgers, Kristen].
5. Paul Paik A.H., Lu W., Natasha R., Marc L., et al. Multipllex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol 2012, 30. (Suppl.: abstr 7505).
6. Johnson F.M., Bekele B.N., Feng L., et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:4609-4615.
7. Haura E.B., Tanvetyanon T., Chiappori A., et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1387-1394.